Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 7.6% – Should You Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s share price shot up 7.6% during trading on Wednesday . The company traded as high as $0.26 and last traded at $0.26. 17,897,355 shares were traded during mid-day trading, a decline of 70% from the average session volume of 59,221,816 shares. The stock had previously closed at $0.24.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on Tonix Pharmaceuticals in a research report on Friday, January 17th. They set a “hold” rating on the stock.

Tonix Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The stock has a market capitalization of $71.60 million, a PE ratio of -0.01 and a beta of 2.02. The stock’s 50 day moving average is $0.27 and its two-hundred day moving average is $0.29.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The business had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. On average, equities analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned approximately 0.12% of Tonix Pharmaceuticals at the end of the most recent quarter. 82.26% of the stock is currently owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.